Fortis Healthcare reported strong financial results for FY26 with revenue up 17% to ₹9,127.84 crore and profit surging 31% to ₹1,064.19 crore. Strategic acquisitions boosted growth, but ongoing legal cases and auditor remarks on internal controls remain points to watch.
Fortis Healthcare Reports Robust FY26 Growth Amidst Regulatory Scrutiny
Fortis Healthcare's revenue reached ₹9,127.84 crore in FY 2026, a significant increase from ₹7,782.75 crore in FY 2025. The company's profit for the year also saw a substantial jump of 31%, rising to ₹1,064.19 crore from ₹809.38 crore in the previous fiscal year.
Reader Takeaway: Strong profit growth driven by acquisitions; monitor legal challenges and auditor comments.
What just happened
Fortis Healthcare announced its financial results for the fiscal year ended March 31, 2026 (FY26). The company reported a consolidated revenue from operations of ₹9,127.84 crore, an increase of 17% compared to ₹7,782.75 crore in FY25. Profit for the year significantly grew to ₹1,064.19 crore from ₹809.38 crore in the prior year. The group also recognized an exceptional loss of ₹22.24 crore, which included a ₹55.18 crore impact from new labour codes.
Why this matters
These results demonstrate Fortis Healthcare's ability to grow its top and bottom lines, indicating strong operational performance. The strategic acquisitions made during the year have contributed to this expansion. However, the company is also managing significant legal and regulatory challenges.
The backstory
Fortis Healthcare has been expanding its hospital network through acquisitions. In July 2025, Fortis Hospotel Limited acquired Shrimann Superspecialty Hospital for ₹468.36 crore. Subsequently, in January 2026, International Hospital Limited acquired TMI Healthcare Private Limited (People Tree Hospital) for ₹433.86 crore. These moves align with the company's strategy to consolidate its market position.
What changes now
Investors will be looking for continued performance improvement and successful integration of acquired assets. The company's proactive approach to addressing regulatory investigations and legal matters will be crucial for sustained investor confidence.
Risks to watch
The company faces substantial legal and regulatory contingencies, with contingent liabilities (not provided for) amounting to ₹2,909.60 crore as of March 31, 2026. These include ongoing tax disputes, medical negligence claims, and investigations by the SFIO and EOW. Additionally, auditors noted control weaknesses related to the 'audit trail' feature in certain group companies.
Peer comparison
(No specific peer comparison data provided in the filing.)
Context metrics (time-bound)
- Revenue (FY 2026): ₹9,127.84 crore
- Revenue (FY 2025): ₹7,782.75 crore
- Profit for the Year (FY 2026): ₹1,064.19 crore
- Profit for the Year (FY 2025): ₹809.38 crore
- Shrimann Superspecialty Hospital acquisition: July 2025 (₹468.36 crore)
- People Tree Hospital acquisition: January 2026 (₹433.86 crore)
- Contingent Liabilities (March 31, 2026): ₹2,909.60 crore
What to track next
Investors should monitor the company's progress in resolving legal and regulatory issues, the integration of recent acquisitions, and any further updates on internal control improvements.